髓过氧化物酶对胸痛患者的早期评估没有帮助。

Myeloperoxidase is not useful for the early assessment of patients with chest pain.

机构信息

Department of Medical Sciences, Cardiology, Uppsala University Hospital and Uppsala Clinical Research Center, Uppsala, Sweden.

出版信息

Clin Biochem. 2010 Feb;43(3):240-5. doi: 10.1016/j.clinbiochem.2009.09.026. Epub 2009 Oct 12.

DOI:10.1016/j.clinbiochem.2009.09.026

PMID:19822136

Abstract

BACKGROUND

Myeloperoxidase (MPO) has been listed as a potentially useful risk marker in acute coronary syndrome. However, its clinical utility in patients with acute chest pain is not yet defined.

DESIGN AND METHODS

MPO (Architect, Abbott Diagnostics) was measured in 120 healthy controls and 303 chest pain patients who had been admitted to the coronary care units of three Swedish hospitals.

RESULTS

Chest pain patents had significantly higher median MPO levels compared to healthy controls (120.6 vs. 78. 9 pmol/L; p<0.001). However, MPO was not useful for the diagnosis of myocardial infarction (c-statistics 0.61 [95% CI 0.54-0.67]), and Cox regression analysis revealed no independent association between MPO and mortality (adjusted hazard ratio 1.3 [95% CI 0.8-2.0]) or the composite endpoint (adjusted hazard ratio 1.1 [95% CI 0.8-1.5]) after a median follow-up of 4.9 years.

CONCLUSIONS

MPO provided no clinically relevant information in the present population of chest pain patients.

摘要

背景

髓过氧化物酶（MPO）已被列为急性冠状动脉综合征中一种有潜在应用价值的风险标志物。然而，其在急性胸痛患者中的临床应用价值尚不清楚。

设计与方法

在三个瑞典医院的冠心病监护病房中，我们测量了 120 例健康对照者和 303 例胸痛患者的 MPO（Architect，雅培诊断）。

结果

胸痛患者的 MPO 中位数水平显著高于健康对照者（120.6 与 78.9 pmol/L；p<0.001）。然而，MPO 对心肌梗死的诊断没有帮助（c 统计量为 0.61 [95%CI 0.54-0.67]），Cox 回归分析显示，MPO 与死亡率（调整后的危险比为 1.3 [95%CI 0.8-2.0]）或复合终点（调整后的危险比为 1.1 [95%CI 0.8-1.5]）之间没有独立关联，中位随访时间为 4.9 年。